FDA Plan To Harmonize Advice On NSAID GI Injury Assessments Draws Cmte. Rebuff
Executive Summary
FDA’s bid to harmonize two review divisions’ regulatory approaches to assessing and preventing gastrointestinal toxicity caused by non-steroidal anti-inflammatory drugs has been thrown a curve by the agency’s outside experts.